Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 27; 77(13):1253-62.
View in:
PubMed
subject areas
Administration, Oral
Aged
Aged, 80 and over
Alzheimer Disease
Amyloid beta-Peptides
Apolipoprotein E4
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Humans
Inositol
Magnetic Resonance Imaging
Male
Mental Status Schedule
Middle Aged
Peptide Fragments
Platelet Aggregation Inhibitors
Time Factors
Treatment Outcome
authors with profiles
Reisa Anne Sperling, M.D.